Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED)

Inclusion Criteria

• •Participants with chronic hepatitis C
• •At least 18 years old
• •Treatment-naïve or relapse to interferon monotherapy
• •Platelets \>= 100,000/mm\^3
• •Neutrophil counts \>= 1,500/ mm\^3
• •Thyroid Stimulating Hormone (TSH) must be within normal limits
• •Hemoglobin \>= 12 gr/dl (females); \>= 13 gr/dl (males)
• •Intravenous drug abusers (Ex-IVDA) participants being under stable substitution for at least 6 months
• •Women of childbearing potential must have a routine pregnancy test performed monthly during treatment and for 7 months thereafter. Sexually active female participants of childbearing potential must be practicing adequate contraception (intrauterine device, oral contraceptives, implanted contraceptives, surgical sterilization, barrier method, or monogamous relationship with a male partner who has had a vasectomy or is using a condom (+ spermicide) during the treatment period and for 7 months after stopping treatment
• •Sexually active male participants must be practicing acceptable methods of contraception (vasectomy, use of condom + spermicide, monogamous relationship with a female partner who practices an acceptable method of contraception) during the treatment period and for 7 months after stopping treatment